RBC Capital Maintains Outperform on Verrica Pharmaceuticals, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Verrica Pharmaceuticals (NASDAQ:VRCA) but lowers the price target from $14 to $13.
August 15, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Verrica Pharmaceuticals but lowers the price target from $14 to $13.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100